<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00650442</url>
  </required_header>
  <id_info>
    <org_study_id>ESTR-02133</org_study_id>
    <nct_id>NCT00650442</nct_id>
  </id_info>
  <brief_title>Evaluation of Adhesion Quality and Irritation of an Alternate Second Generation Estradiol Transdermal System</brief_title>
  <official_title>Evaluation of the Adhesion Quality and Primary Dermal Irritation Potential of an Alternate Second Generation Estradiol Transdermal Systems in Normal Healthy Female Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mylan Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mylan Pharmaceuticals</source>
  <brief_summary>
    <textblock>
      The primary objective of this study was to compare the adhesive quality of the current Mylan
      estradiol placebo transdermal system, with that of an alternate second generation Mylan
      estradiol placebo transdermal system following a single system application. As a secondary
      objective, primary dermal irritation was assessed after removal of each transdermal system.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2003</start_date>
  <completion_date type="Actual">February 2003</completion_date>
  <primary_completion_date type="Actual">February 2003</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Transdermal Adhesion</measure>
    <time_frame>within 30 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Estradiol Transdermal System Placebo - Alternate Adhesive</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Estradiol Transdermal System Placebo - Current Adhesive</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estradiol Transdermal System Placebo - Alternate Adhesive</intervention_name>
    <description>single application</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estradiol Transdermal System Placebo - Current Adhesive</intervention_name>
    <description>single application</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age: 40-66 years.

          2. Sex: Females only.

          3. Weight: At least 52 kg (115 lbs) and within 20% of Ideal Body Weight (IBW), as
             referenced by the Table of &quot;&quot;Desirable Weights of Adults&quot;&quot; from Metropolitan Life
             Insurance Company, 1999 (See Part II: ADMINISTRATIVE ASPECTS OF HUMAN DERMAL SAFETY
             STUDY PROTOCOLS).

          4. All subjects should be judged normal and healthy during a prestudy medical evaluation
             (physical examination, laboratory evaluation and 12-lead ECG) performed within 14 days
             of the initial patch application.

        Exclusion Criteria:

          1. Institutionalized subjects will not be used.

          2. Any prior history of skin diseases (eczema, psoriasis, atopic dermatitis).

          3. Damaged skin in or around test sites that include sunburn, uneven skin tones, tattoos,
             scars or other disfigurations of the test site.

          4. Abnormal and clinically significant laboratory test results:

               1. Clinically significant deviation from the Guide to Clinically Relevant
                  Abnormalities (See Part II: ADMINISTRATIVE ASPECTS OF HUMAN DERMAL SAFETY STUDY
                  PROTOCOLS).

               2. Abnormal and clinically relevant ECG tracing.

          5. Subjects who have received an investigational drug within 30 days prior to the initial
             patch application and/or participated in any transdermal system test for irritation or
             sensitization within the last 4 weeks.

          6. Allergy or hypersensitivity to any tapes or adhesives (ex. band-aids, medical tape).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>66 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas S Clark, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kendle International Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kendle International Inc.</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mpibiostudies.com</url>
    <description>Mylan Pharmaceuticals Inc. - Clinical Trial Results</description>
  </link>
  <link>
    <url>http://dailymed.nlm.nih.gov/dailymed/about.cfm</url>
    <description>Daily Med - posting of most recent submitted labelling to the Food and Drug Administration (FDA) and currently in use</description>
  </link>
  <link>
    <url>http://www.fda.gov/opacom/7alerts.html</url>
    <description>Recalls, Market Withdrawals and Safety Alerts</description>
  </link>
  <link>
    <url>http://www.fda.gov/opacom/Enforce.html</url>
    <description>FDA Enforcement Report Index</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Medwatch, FDA Safety Information and Adverse Event Reporting Program</description>
  </link>
  <verification_date>March 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 30, 2008</study_first_submitted>
  <study_first_submitted_qc>March 31, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2008</study_first_posted>
  <last_update_submitted>March 31, 2008</last_update_submitted>
  <last_update_submitted_qc>March 31, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 1, 2008</last_update_posted>
  <responsible_party>
    <name_title>Will Sullivan, Global Head of Product Risk and Safety Management</name_title>
    <organization>Mylan Inc.</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

